ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 638

Assessment of Myocardial Abnormalities in Primary Sjögren Syndrome Using a Comprehensive Cardiac Magnetic Resonance Approach

Natsumi Ikumi1, Hitomi Kobayashi2, Yasuyuki Kobayashi3, Hirotake Inomata4, Yosuke Nagasawa4, Kaita Sugiyama4, Hiromi Karasawa1, Takamasa Nozaki4, Hidetaka Shiraiwa4, Mitsuhiro Iwata2, Noboru Kitamura5, Yoshihiro Matsukawa1 and Masami Takei2, 1Division of Heamatology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 2Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, 3Advanced Biomedical Imaging Informatics, St.Marianna University School of Medicine, Kawasaki, Japan, 4Nihon University School of Medicine, Tokyo, Japan, 5NIhon University School of Medicine, Tokyo, Japan

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: magnetic resonance imaging (MRI) and myocardial involvement, Raynaud's phenomenon, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2015

Title: Sjögren's Syndrome Poster I: Clinical Insights into Sjögren's Syndrome

Session Type: ACR Poster Session A

Session Time: 9:00AM-11:00AM

Background/Purpose: Primary Sjögren syndrome (pSS) shares many clinical, inflammatory, and immunological features with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). SLE and RA are characterized by a high risk of cardiac involvement. However, there are limited data on the risk of overt cardiac involvement in pSS. We sought to use a cardiac magnetic resonance imaging (CMR) approach to assess cardiac involvement and determine its association with disease characteristics in pSS patients without cardiac symptoms.

Methods: Consecutive pSS patients, according to ACR classification criteria (2012), without a history or clinical findings of hypertension, cardiovascular disease, diabetes, or dyslipidemia underwent contrast CMR. Late gadolinium enhancement (LGE) was obtained for the assessment of myocardial fibrosis. Using a black-blood T2-weighted image (T2-WI), myocardial inflammation could be assessed. Sjögren syndrome disease activity index (ESSDAI) was determined. Eighty percent patients had documentation of a minor salivary gland biopsy. Salivary gland biopsy data were classified by focus score (FS). We investigated the patients in terms of prevalence of CMR abnormalities and explored possible associations between CMR abnormalities and pSS disease characteristics.

Results: Thirty-six female pSS patients were enrolled (mean age: 55.9 ± 7.1 years). On average, cardiovascular risk was low for the group, with patients demonstrating no ECG abnormalities, and the patients had generally low traditional cardiovascular risk factors, with a mean Framingham 10-year hard cardiovascular risk score of 4% ± 2%. The mean ESSDAI was 3.5 ± 2.1. Twelve pSS patients (33%) demonstrated myocardial abnormalities. T2-WI was seen in 4 pSS patients (11%). LGE was found in 11 pSS patients (30%), 3 of whom also demonstrated T2-WI. The main finding observed in 7 of these 11 patients (63%) was a linear pattern without coronary distribution. A patchy nodular enhancement pattern was observed in 4 patients (36%). Compared with LGE- and T2-WI-negative patients, LGE- and T2-WI-positive patients showed no significant difference related to ESSDAI. Anti-SSB antibodies were significantly higher in LGE-positive than LGE-negative patients (p = 0.002). Raynaud phenomenon was significantly associated with LGE- and T2-WI-positive patients (p = 0.006 and p = 0.04, respectively). Other pSS characteristics such as disease duration, commodities, and cardiovascular risk factors were not significantly associated with myocardial abnormalities. The greatest relative difference between LGE-positive and -negative patients was observed in focus score ≥ 3, with an adjusted odds ratio of 3.0. After adjusting for confounding by age, pSS duration, and anti-SSB antibodies, the association of LGE with Raynaud phenomenon remained significant (p = 0.023).

Conclusion: Subclinical myocardial involvement, as detected by cardiac MRI, was frequent in pSS patients without cardiac symptoms. Our results suggest that Raynaud phenomenon has a role in promoting cardiac involvements in patients with pSS.


Disclosure: N. Ikumi, None; H. Kobayashi, None; Y. Kobayashi, None; H. Inomata, None; Y. Nagasawa, None; K. Sugiyama, None; H. Karasawa, None; T. Nozaki, None; H. Shiraiwa, None; M. Iwata, None; N. Kitamura, None; Y. Matsukawa, None; M. Takei, None.

To cite this abstract in AMA style:

Ikumi N, Kobayashi H, Kobayashi Y, Inomata H, Nagasawa Y, Sugiyama K, Karasawa H, Nozaki T, Shiraiwa H, Iwata M, Kitamura N, Matsukawa Y, Takei M. Assessment of Myocardial Abnormalities in Primary Sjögren Syndrome Using a Comprehensive Cardiac Magnetic Resonance Approach [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/assessment-of-myocardial-abnormalities-in-primary-sjogren-syndrome-using-a-comprehensive-cardiac-magnetic-resonance-approach/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/assessment-of-myocardial-abnormalities-in-primary-sjogren-syndrome-using-a-comprehensive-cardiac-magnetic-resonance-approach/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology